Connection

John Kaczmar to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications John Kaczmar has written about Antibodies, Monoclonal, Humanized.
John Kaczmar
Connection Strength
0.196
Antibodies, Monoclonal, Humanized
  1. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 04 01; 28(7):1345-1352.
    View in: PubMed
    Score: 0.196
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.